Back to top
more

Ocugen (OCGN)

(Delayed Data from NSDQ)

$1.96 USD

1.96
15,579,272

+0.26 (15.29%)

Updated May 15, 2024 04:00 PM ET

After-Market: $1.94 -0.02 (-1.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is the Options Market Predicting a Spike in Ocugen (OCGN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US

by Zacks Equity Research

Ocugen (OCGN) selects Jubilant HollisterStier as its manufacturing partner for its COVID-19 vaccine candidate, Covaxin, in the United States and Canada.

Company News for Jun 16, 2021

by Zacks Equity Research

Companies In The News Are: BA, MSTR, OCGN, F

Ocugen (OCGN) to File Coronavirus Vaccine BLA in US, Stock Tanks

by Zacks Equity Research

Ocugen (OCGN) to submit a BLA for its COVID-19 vaccine candidate, Covaxin, in the United States. The company will no longer pursue an EUA for the vaccine candidate. Shares fall.

Aditi Saraogi headshot

Are Options Traders Betting on a Big Move in Ocugen (OCGN) Stock?

by Aditi Saraogi

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Ocugen (OCGN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year

by Zacks Equity Research

Ocugen's (OCGN) stock rides on the company's collaboration with India's Bharat Biotech to co-develop and commercialize the latter's COVID-19 vaccine, COVAXIN, for the U.S. market.

The Zacks Analyst Blog Highlights: BioNTech, Ocugen, Rubius Therapeutics and Entera Bio

by Zacks Equity Research

The Zacks Analyst Blog Highlights: BioNTech, Ocugen, Rubius Therapeutics and Entera Bio

Kinjel Shah headshot

4 Biotech Stocks That Have Already Doubled This Year So Far

by Kinjel Shah

Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.

Is the Options Market Predicting a Spike in Ocugen (OCGN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

Ocugen (OCGN) Miss Earnings & Revenues Estimates in Q1

by Zacks Equity Research

Ocugen (OCGN) miss earnings and revenues estimates in the first quarter of 2021. Stock down.

Kinjel Shah headshot

Drug/Biotech Stock Q1 Earnings on May 7: RDUS, CRON & OCGN

by Kinjel Shah

Let us take a look at three small biotech companies, RDUS, CRON and OCGN, which are gearing up for their earnings release.

Sweta Jaiswal, FRM headshot

Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus

by Sweta Jaiswal, FRM

Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.

Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Ocugen (OCGN) is likely to provide update related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports first-quarter 2021 results.

Ocugen (OCGN) Up on Positive Data for COVID-19 Vaccine Candidate

by Zacks Equity Research

Ocugen (OCGN) gains as partner Bharat Biotech shared positive results of the second interim analysis of its phase III study of COVAXIN.

Are Options Traders Betting on a Big Move in Ocugen (OCGN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

Ocugen (OCGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Ocugen (OCGN) closed the most recent trading day at $6.70, moving -1.33% from the previous trading session.

Ocugen (OCGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Ocugen (OCGN) closed the most recent trading day at $9.90, moving -1% from the previous trading session.

Ocugen (OCGN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Ocugen (OCGN) closed at $8.63 in the latest trading session, marking a -1.26% move from the prior day.

Ocugen (OCGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Ocugen (OCGN) will provide updates on its pipeline when it reports fourth-quarter 2020 results.

Ocugen (OCGN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Ocugen (OCGN) closed at $10.17 in the latest trading session, marking a -0.59% move from the prior day.

Company News for Dec 23, 2020

by Zacks Equity Research

Companies in the news are: PTON, OCGN, SPWH, FEYE

Ocugen (OCGN) Soars: Stock Adds 6.6% in Session

by Zacks Equity Research

Ocugen (OCGN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Ocugen (OCGN) Looks Good: Stock Adds 5.5% in Session

by Zacks Equity Research

Ocugen (OCGN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

What Makes Ocugen (OCGN) a New Strong Buy Stock

by Zacks Equity Research

Ocugen (OCGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.